ARCHIVES

“Treatment INDs” Seen As Major Threat To Clinical Trials

This article is from The Cancer Letter archive.

Vol. 13 No. 34 | August 21, 1987

Download PDF Visit The Full Archive

Related Articles

Two-Year Remission While Taking Gleevec Puts Patients Into Normal Mortality Rate

March 25, 2011

FCRF Recompetition Notice Of Intent

September 19, 1980

Peer Review Study Team Plans Hearing

December 12, 1975

NCI, ACS Agree On Interim Mammography Guides Dropping Routine Use for Women Under Age 50

August 27, 1976

DOD Funds 17 Ovarian Cancer Research Grants.

June 20, 2003

Letters: Broder Response To Waxman Called Political Back-Pedaling

February 11, 1994